Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-21-020250

Executive VP, Head of R&D gave up 2,141 shares (to pay taxes)

  • Executive VP, Head of R&D acquired 4,583 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Ho Tony W Executive VP, Head of R&D 2021-03-10 Option exercise +4,583 40,445 D: show line 1 in the form
Ho Tony W Executive VP, Head of R&D 2021-03-10 Shares withheld for taxes −2,141 $124.15 $265,805 38,304 D: show line 2 in the form

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Ho Tony W Executive VP, Head of R&D 2021-03-11 Grant or award · Stock Option (Right to Buy) +23,334 23,334 D: show line 3 in the form
Ho Tony W Executive VP, Head of R&D 2021-03-11 Grant or award · Restricted Stock Units +9,000 9,000 D: show line 4 in the form
Loading xslF345X03/doc4.xml…